Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-β signaling by recruiting Rab5c

被引:0
作者
Yi-ming Li
Cong Xu
Bo Sun
Fang-jing Zhong
Momo Cao
Lian-yue Yang
机构
[1] Xiangya Hospital,Liver Cancer Laboratory, Department of Surgery
[2] Central South University,undefined
来源
Cancer Cell International | / 22卷
关键词
Piezo1; Hepatocellular carcinoma; Prognosis; Cancer progression; TGF-β signaling; EMT;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 183 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2020)Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition) Liver Cancer 9 682-720
[3]  
Soerjomataram I(2019)A global view of hepatocellular carcinoma: trends, risk, prevention and management Nat Rev Gastroenterol Hepatol 16 589-604
[4]  
Zhou J(2018)Hepatocellular carcinoma Lancet 391 1301-1314
[5]  
Sun H(2020)Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma Cell 249 118-123
[6]  
Wang Z(2009)Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection Ann Surg 272 574-581
[7]  
Yang JD(2020)Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the Milan criteria Ann Surg 156 477-91 e1
[8]  
Hainaut P(2019)Epidemiology and management of hepatocellular carcinoma Gastroenterology 49 3412-3419
[9]  
Gores GJ(2013)Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study EurJ Cancer (Oxford, England: 1990) 56 1330-1335
[10]  
Forner A(2012)Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design J Hepatol 74 96-108